Athenex announced preliminary data showing early clinical responses in the first part of a two part study of Oraxol monotherapy in patients with unresectable cutaneous angiosarcoma. To date, 10 patients have been enrolled in the clinical study, which is being conducted in four sites in the U.S. and Hong Kong. The first seven patients have received at least six weeks of treatment, which is the timepoint for the first response assessment; three patients have not yet reached the first assessment timepoint. Oraxol is being administered once daily for three consecutive days every week during the treatment period. All seven patients showed significant and visible reduction of the cutaneous angiosarcoma within one or two weeks of treatment. Three patients had complete responses based on Recist v1.1 criteria, with two complete responses occurring by six weeks of treatment. None of the patients enrolled have discontinued treatment due to death, disease progression, or adverse events. No peripheral neuropathy has been reported. Based on the preliminary data, the study has met the criteria required to proceed to full enrollment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.